Quick Answer
ArriVent BioPharma, Inc. reported R&D Expense of $153.35 million for fiscal year 2025.
ArriVent BioPharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $153.35M | +94.1% |
| 2024 | $79.00M | +21.8% |
| 2023 | $64.88M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $32.17M | +60.1% | +16.0% |
| June 30, 2025 | $27.72M | +27.3% | -54.8% |
| March 31, 2025 | $61.29M | +261.1% | +205.1% |
| September 30, 2024 | $20.09M | +40.7% | -7.8% |
| June 30, 2024 | $21.78M | +7.0% | +28.3% |
| March 31, 2024 | $16.98M | +65.8% | +18.9% |
| September 30, 2023 | $14.28M | — | -29.9% |
| June 30, 2023 | $20.36M | — | +98.9% |
- ArriVent BioPharma, Inc. showed an increase of +94.1% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, ArriVent BioPharma, Inc.’s r&d expense has grown by 136.3% (from $64.88 million to $153.35 million).
- The most recent figure is from ArriVent BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: